This proposal seeks continuation of support for long-term studies of molecules responsible for regulation of thrombosis by the protein C pathway. Hereditary protein C (PC) and protein S deficiencies are associated with thrombotic disease and activated protein C (APC) exhibits potent antithrombotic activity in animal models of thrombosis. APC is a normal circulating component in human blood which probably regulates basal levels of thrombin generation in vivo. Clinical trials of PC concentrates for antithrombotic therapy have been initiated. Plasma from many thrombophilia patients gives a poor anticoagulant response to APC. This property of plasma, called """"""""APC resistance"""""""", is the most common identifiable defect among venous thrombophilia patients. This proposal will test the hypothesis, based on our preliminary results, that abnormal factor V is responsible for APC resistance. Another hypothesis to be tested is that molecular mechanisms for the regulation of the anticoagulant activity of PC and APC are determined by specific amino acids on the surface of PC and APC. Thus, the five specific aims include the following. (1) To characterize abnormalities of factor V hypothesized to be responsible for APC resistance, we will sequence patients' factor V cDNA and perform studies involving purification and characterization of normal and patients' factor V to identify abnormalities at the molecular level. (2) To extend analysis of three-dimensional homology models to the entire molecules of PC and APC and to APC:serpin complexes, we will continue development of computer modelling studies to provide models which will be used to explain clinical phenotypes for naturally occurring mutations and to design and interpret structure-function studies. (3) To identify functional roles of specific surface loops of residues of PC and APC, we will use synthetic oligopeptides and polypeptides and antipeptide antibodies to identify essential sites and residues on the surface of PC and APC. Studies will employ synthetic oligopeptides and polypeptides, including among other, synthetic individual N- and C-terminal EGF domains, chemically-ligated polypeptides containing both EGF domains, and synthetic peptides containing the putative Ca2+-binding loop of the protease domain (residues 225-235). (4) To identify functionally essential residues at specific surface sites of PC and APC, we will use site-directed mutagenesis. Studies will focus on amino acids hypothesized to be involved in Ca2+-ion binding by the protease domain and in intermolecular interactions of PC or APC with thrombin:thrombomodulin, factor Va, and protein S. The roles of positive residues in a novel exosite will be probed. New inhibitor-resistant APC mutants will be sought. Studies will include defining the mechanism of anticoagulant action of the inhibitor-resistant mutant, S360A-APC, and using this molecule to study interactions of APC with normal and abnormal factor Va and with protein S. (5) To prepare PC and APC crystals suitable for x-ray diffraction determination of their three-dimensional structures. The proposed studies will provide new knowledge about natural anticoagulant mechanisms and may lead to new approaches to control thrombosis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37HL052246-03
Application #
2029114
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1994-12-01
Project End
1999-11-30
Budget Start
1996-12-01
Budget End
1997-11-30
Support Year
3
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Healy, Laura D; Rigg, Rachel A; Griffin, John H et al. (2018) Regulation of immune cell signaling by activated protein C. J Leukoc Biol :
Griffin, John H; Zlokovic, Berislav V; Mosnier, Laurent O (2018) Activated protein C, protease activated receptor 1, and neuroprotection. Blood 132:159-169
Sinha, Ranjeet K; Wang, Yaoming; Zhao, Zhen et al. (2018) PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke. Blood 131:1163-1171
Gupta, Naveen; Liu, Roland; Shin, Stephanie et al. (2018) SCH79797 improves outcomes in experimental bacterial pneumonia by boosting neutrophil killing and direct antibiotic activity. J Antimicrob Chemother 73:1586-1594
Prince, Raja; Bologna, Luca; Manetti, Mirko et al. (2018) Targeting anticoagulant protein S to improve hemostasis in hemophilia. Blood 131:1360-1371
Gupta, Naveen; Sinha, Ranjeet; Krasnodembskaya, Anna et al. (2018) The TLR4-PAR1 Axis Regulates Bone Marrow Mesenchymal Stromal Cell Survival and Therapeutic Capacity in Experimental Bacterial Pneumonia. Stem Cells 36:796-806
Nazir, Sumra; Gadi, Ihsan; Al-Dabet, Moh'd Mohanad et al. (2017) Cytoprotective activated protein C averts Nlrp3 inflammasome-induced ischemia-reperfusion injury via mTORC1 inhibition. Blood 130:2664-2677
Deguchi, Hiroshi; Navarro, Silvia; Payne, Amanda B et al. (2017) Low level of the plasma sphingolipid, glucosylceramide, is associated with thrombotic diseases. Res Pract Thromb Haemost 1:33-40
Fernández, José A; Xu, Xiao; Sinha, Ranjeet K et al. (2017) Activated protein C light chain provides an extended binding surface for its anticoagulant cofactor, protein S. Blood Adv 1:1423-1426
Deguchi, Hiroshi; Banerjee, Yajnavalka; Elias, Darlene J et al. (2016) Elevated CETP Lipid Transfer Activity is Associated with the Risk of Venous Thromboembolism. J Atheroscler Thromb 23:1159-1167

Showing the most recent 10 out of 76 publications